In PROVE IT-TIMI 22 , the incidence was 9.4 % for subjects randomized to atorvastatin 80 mg/day and 10.6 % for subjects randomized to pravastatin 40 mg/day ( OR , 0.88 ; 95 % CI , 0.71 to 1.09 ; P = 0.25 ) .